Clinical trials: CVD - Cardiovascular Disease
Aortic Aneurysm, Aortic Dissection
Thoraflex™ Hybrid IDE Study
The study will assess the effectiveness, safety and clinical outcomes of the Thoraflex™ Hybrid Device in the treatment of aortic disease affecting the aortic arch and the descending thoracic aorta, with or without involvement of…
- Conditions
- Aortic Aneurysm, Aortic Dissection, Aortic Rupture
- Trial name
- NCT02724072
- Testing
- Thoraflex™ Hybrid Device
- Where
- 12 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bolton Medical
Venous Thrombosis, Pediatrics
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
The first study with rivaroxaban in pediatric subjects is a Phase I study, where the pharmacokinetic/pharmacodynamic (PK/PD) profile of rivaroxaban will be investigated to confirm that the exposure is comparable to adults.
- Trial name
- NCT01145859
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 36 sites in United States, Australia and 8 more
- Volunteers
- 59 people
- Sponsor
- Bayer
Acute Coronary Syndrome, Angina Pectoris
Diagnostic Performance of Artificial Intelligence Algorithms in Prediction of Acute Coronary Syndrome Based on White Blood Cell Properties
The goal of this observational study is to evaluate whether artificial intelligence (AI) algorithms can predict or exclude acute coronary syndrome (ACS) in adults using data generated by routine hematology testing.
- Conditions
- Acute Coronary Syndrome, Angina Pectoris, NSTEMI - Non-ST Segment Elevation MI, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT06384846
- Where
- Austria
- Volunteers
- 3,350 people, healthy volunteers welcome
- Sponsor
- RobotDreams GmbH
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
This is a multicenter, single-arm trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT03012646
- Testing
- Inhaled Treprostinil
- Sponsor
- United Therapeutics
Multiple Myeloma
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CS1 cCAR in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT04156269
- Testing
- BCMA-CS1 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- iCell Gene Therapeutics
Venous Malformations, Lymphatic Malformations
A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
This is a phase 3, double-blind, randomized, placebo-controlled, parallel group, adaptive, multicenter study planned to be conducted at multiple sites in North America, Canada, Taiwan and South Korea.
- Conditions
- Venous Malformations, Lymphatic Malformations, Klippel-Trenaunay Syndrome, CLOVES Syndrome
- Trial name
- S-KY (NCT07285005)
- Testing
- KP-001
- Where
- 5 sites in United States, South Korea and 1 more
- Volunteers
- 150 people
- Sponsor
- Kaken Pharmaceutical
Carotid Artery Disease
Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)
The primary objective of this study is to assess the outcomes of stenting with distal protection in the treatment of obstructive carotid artery disease during peri-approval/initial commercialization in relation to the outcomes of…
- Trial name
- NCT00231231
- Testing
- -PRECISE Nitinol Stent System (5F, 5.5F and 6F), ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Cordis US Corp.
Autoimmune Diseases, Cardiovascular Disorders
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions.
- Conditions
- Autoimmune Diseases, Cardiovascular Disorders, Diabetes Complications, Integumentary Disease
- Trial name
- NCT04684602
- Testing
- PrimePro™/ PrimeMSK™
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Thomas Advanced Medical LLC
Venous Thrombosis
A Study of MK-2060 in Healthy Participants (MK-2060-016)
The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.
- Trial name
- NCT06582602
- Testing
- MK-2060
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Aortic Valve Disease, Coronary Artery Disease (CAD)
Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol
The objective of this investigation is to compare the cardioprotective effects and safety of two cardioplegic solutions, HTK Cardioplegic Solution (Custodiol) and Custodiol-N in patients undergoing aortic valve surgery.
- Trial name
- Custodiol-AV (NCT02098772)
- Testing
- Custodiol-N, Custodiol
- Where
- 6 sites in Germany
- Volunteers
- 530 people
- Sponsor
- Dr. F. Köhler Chemie GmbH
Hypertension
SHINE: Trends and Satisfaction in Hypertensives Using Aktiia Optical BP Monitoring Device (SHINE)
The SHINE study aims to gather data on the evolution of participant's blood pressure and to correlate this with demographic, lifestyle and health factors in a hypertensive population as well as, to gather data on participants'…
- Trial name
- SHINE (NCT06356077)
- Where
- United Kingdom
- Volunteers
- 1,729 people
- Sponsor
- Aktiia SA
Multiple Myeloma
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
The purpose of this study is to determine if the addition of daratumumab to VELCADE-melphalan-prednisone (VMP) will improve very good partial response (VGPR) or better compared with VMP alone.
- Trial name
- NCT03217812
- Testing
- Velcade, Melphalan, Prednisone
- Where
- 44 sites in China, Hong Kong and 3 more
- Volunteers
- 220 people
- Sponsor
- Janssen Research & Development, LLC
Venous Leg Ulcer
A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers
This study is a multicenter, prospective, randomized, placebo controlled, adaptive design study performed to assess the safety and the efficacy of 5% EscharEx (EX-02) compared to Gel Vehicle (placebo) and non-surgical standard of…
- Trial name
- NCT03588130
- Testing
- EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC)
- Where
- 22 sites in United States, Switzerland
- Volunteers
- 120 people
- Sponsor
- MediWound Ltd
Coronary Artery Disease
CorPath™ 200: Robotically-Assisted Percutaneous Coronary Intervention (PCI)
An open-label, prospective, single-arm study is designed to evaluate safety, clinical and technical efficacy of the CorPath 200 System in delivery and manipulation of the coronary guide wires and balloon/stent systems for use in…
- Trial name
- NCT01076036
- Testing
- CorPath 200
- Where
- Colombia
- Volunteers
- 8 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
Blepharospasm, Hemifacial Spasm
Post Marketing Surveillance Study of Dysport
The purpose of this study is to provide further information regarding the risks and benefits of Dysport in marketed indications.
- Conditions
- Blepharospasm, Hemifacial Spasm, Cervical Dystonia, Spasmodic Torticollis
- Trial name
- NCT00210431
- Where
- 36 sites in France, Germany and 1 more
- Volunteers
- 783 people
- Sponsor
- Ipsen
Arteriovenous Fistula
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A study to evaluate the efficacy of SRM003 treatment versus participating sites' standard practice treatment in improving the rate of AVF maturation and use in subjects with end-stage renal disease undergoing surgery for creation…
- Trial name
- NCT01806545
- Testing
- SRM003, Participating Site's standard practice
- Where
- 47 sites in United States
- Volunteers
- 64 people
- Sponsor
- Shire
Relapsed or Refractory Multiple Myeloma
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in…
- Trial name
- NCT06055075
- Testing
- Forimtamig, Carfilzomib, Daratumumab
- Where
- 8 sites in Australia, Canada and 4 more
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06072001
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Cardiovascular Disease
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for…
- Trial name
- NCT07136012
- Testing
- Olpasiran
- Where
- 252 sites in United States, Australia and 1 more
- Volunteers
- 11,000 people
- Sponsor
- Amgen
Fabry Disease
A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme.
- Trial name
- NCT00312767
- Testing
- Fabrazyme (agalsidase beta)
- Where
- United States
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.